Alkermes Plc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 12, 2026, details the completion of Alkermes Plc.'s acquisition of Avadel Pharmaceuticals plc ("Avadel") and the associated financing arrangements. The transaction was finalized via a court-sanctioned scheme of arrangement under Irish law, effective February 12, 2026.
Key Financial Metrics and Transaction Terms
- Acquisition Consideration: Alkermes acquired all outstanding Avadel shares for $21.00 in cash per share.
- Contingent Value Rights (CVRs): Shareholders received one non-transferable CVR per share, entitling them to a potential additional $1.50 per share upon achieving specific milestones.
- Financing Structure: Alkermes entered into a new Credit Agreement providing $1.525 billion in total term loans, fully drawn on the closing date.
- Term Loan A (TLA): $750 million; matures February 12, 2031.
- Term Loan B (TLB): $775 million; matures August 12, 2031.
- Interest Rates:
- TLA: Term SOFR + 2.75% (initially) or Alternate Base Rate + 1.75% (initially).
- TLB: Term SOFR + 2.75% or Alternate Base Rate + 1.75%.
- Debt Covenants: The agreement requires maintenance of a maximum Secured Net Leverage Ratio and a minimum Consolidated Interest Coverage Ratio (excluding TLB Facility).
Material Changes Versus Prior Period
- Termination of Bridge Financing: Alkermes terminated a previously disclosed $1.5 billion bridge term loan credit agreement dated November 18, 2025, as the new permanent financing and cash on hand were sufficient to fund the acquisition.
- Capital Structure: Avadel is now a wholly-owned subsidiary of Alkermes. Avadel shares have been delisted from the Nasdaq Global Market.
- Equity Awards: Outstanding Avadel equity awards (options, RSUs, restricted stock) were converted to cash and CVRs or cancelled based on the transaction terms.
Outlook, Risks, and Contingencies
- Financial Obligations: The company now carries significant new debt obligations secured by substantially all assets of the borrowers and subsidiary guarantors.
- CVR Liability: Alkermes has a contingent liability to pay up to $1.50 per Avadel share if specific milestones are met prior to the expiration date defined in the CVR Agreement.
- Covenant Compliance: Future financial performance is constrained by the new leverage and interest coverage covenants. Failure to meet these could trigger events of default.
- Pro Forma Data: The filing does not include pro forma financial information or financial statements of the acquired business; these are expected to be filed within 71 calendar days.
Investor Verification Checklist
- Verify the specific milestones and expiration dates for the Contingent Value Rights (CVRs) in the CVR Agreement (Exhibit A to the Transaction Agreement).
- Review the full Credit Agreement (Exhibit 10.1) for detailed definitions of the Secured Net Leverage Ratio and Consolidated Interest Coverage Ratio.
- Monitor the upcoming filing (within 71 days) for pro forma financial information to assess the combined entity's leverage and liquidity.
- Confirm the total cash consideration paid and the number of CVRs issued to calculate the maximum potential acquisition cost.